Compound d16 reduces tumor growth and overcomes therapeutic resistance in mutant p53-bearing cancers

Researchers at Baylor College of Medicine have developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers in the lab. The findings, published in the journal Cancer Research Communications, open opportunities for new combination therapies for these difficult-to-treat cancers.

Joint replacement surgery, arthritis are not inevitable

Don’t worry about your hips or knees as you age. Arthritis in those joints isn’t inevitable. Keep doing the activities you enjoy. Those hopeful words come from Rafael Sierra, M.D., an orthopedic surgeon at Mayo Clinic specializing in hip and knee reconstruction. Dr. Sierra says there is no need to curtail your activities out of fear that you’ll wear out those joints as you age and need joint replacement.

Women seeking credibility in health care feel ‘on trial,’ struggle with constraints of double binds

Having a chronic illness is a great deal of work, communication researchers have long known. But having an illness that is stigmatized, not well understood or not perceived as a priority by clinicians is uniquely burdensome for many women, who find themselves struggling to establish both the legitimacy of their medical problems and their credibility with clinicians, family members and friends, a recent study suggests.

Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine. By providing whole-body quantification of HER2 expression, 68Ga-ABY-025 PET/CT can play a valuable role in treatment planning and could spare patients from unnecessary drug-related side effects.